Relapsing-Remitting Multiple Sclerosis (RRMS) research hub
5 indexed studies · 3 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
This clinical study tests a medicine called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis (RRMS). Doctors want to see how the body absorbs an injection given just under the skin. They are checking if this method is safe, well tolerated, and practical for younger patients.
Poland · Germany · France - recruitingHuman Pharmacology (Phase I)- First administration to humans
Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
This study is testing a new way to treat Relapsing Remitting Multiple Sclerosis (RRMS). It uses your own red blood cells, specially prepared, to see if they are safe and help reduce MS symptoms and new brain lesions. It's an early-stage study, focusing on safety.
Italy · Germany · Czechia - active not recruitingPHASE3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
This study compares a new medicine, ABP 692, with an existing one, Ocrevus, for people with a type of multiple sclerosis (RRMS). It checks if special brain scans and how the medicines act in the body are similar, aiming to offer another treatment option.
United States · Belgium · Bulgaria - not yet recruitingPHASE3
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
This study looks at whether people aged 55 and over with stable relapsing-remitting MS can safely stop their MS medication. It compares continuing treatment to stopping, checking MS activity, quality of life, and disability over two years.
France - recruitingPHASE4
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
This study, called ELIOS, is looking at new ways to track changes in relapsing-remitting multiple sclerosis (RRMS) using eye movements. It aims to see how well these eye movement tests can show if a treatment called ofatumumab is working in Canadian patients.
Canada